Desogestrel And Ethinyl Estradiol Kit
Product Images NDC 79929-006

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Desogestrel And Ethinyl Estradiol (NDC 79929-006). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Naari Pte Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Blister-28s-pack (Blister 28s Pack)

Desogestrel and Ethinyl Estradiol Tablets USP 0.15 mg/0.03 mg 28-Day Kit label. The label shows a 4-week pill calendar with days of the week arranged in columns and weeks in rows, with start arrows for each week. It is manufactured by Naari Pte Ltd and made in India. Storage instructions are also visible at the bottom.*

FDA Label Image

Figure 1 (Deso Ee 02)

A bar chart showing mortality rates (number of deaths per 100,000 woman-years) by age groups (15-24, 25-34, 35-44, 45 and older) for four categories: ever-users (non-smokers), controls (non-smokers), ever-users (smokers), and controls (smokers). Mortality rates increase with age, with the highest rates observed in ever-users (smokers) age 45 and older.*

FDA Label Image

Chemical Structure (Deso Ee Structure)

Chemical structure diagram showing the molecular structures of desogestrel and ethinyl estradiol, the active ingredients in the desogestrel and ethinyl estradiol kit by Naari Pte Limited.*

FDA Label Image

Figure-2 (Fig 2)

A forest plot chart titled 'Risk of Breast Cancer with Combined Oral Contraceptive Use' showing effect estimates (OR/RR) with confidence intervals for multiple studies examining ever use and current use of combined oral contraceptives. Studies listed include NICHD Women's Contraceptive Study, French E3N cohort Study, Shangai Womens Health Study, The Nurses' Health Study II, Oxford Family Planning Association Study, and Danish Sex Hormone Register Study, with effect estimates ranging approximately from 0.9 to 1.3.*

FDA Label Image

Table1-part1 (Table1 Part1)

A data table titled 'Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year, United States.' It presents various contraceptive methods, showing percentages of women experiencing unintended pregnancy during typical and perfect use, and percentages of women continuing use at one year.*

FDA Label Image

Table1-part2 (Table1 Part2)

Text panel discussing contraceptive methods including emergency contraceptive pills, lactation amenorrhea, and contraceptive efficacy. References studies and sources regarding pregnancy risk reduction, usage statistics, treatment schedules, and FDA-approved oral contraceptives for emergency use such as Ovral, Alesse, Nordette, and Levlen. Additional notes on spermicide use and fertility tracking methods are included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.